- Moneycontrol /
- Market /
- Pharmaceuticals /
- HALF YEARLY RESULTS
BSE Live
Feb 20, 16:00Prev. Close
317.90
Open Price
319.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Feb 20, 15:57Prev. Close
318.10
Open Price
318.10
Bid Price (Qty.)
321.55 (664)
Offer Price (Qty.)
0.00 (0)
| Half Yearly Results of Glenmark Pharma (in Rs. Cr.) | Sep '19 | Mar '19 | Sep '18 | Mar '18 | Sep '17 | |
| Net Sales/Income from operations | 3,197.86 | 3,130.66 | 3,000.48 | 2,965.57 | 3,130.48 | |
| Other Operating Income | 90.76 | 88.66 | 85.07 | 258.72 | 77.11 | |
| Total Income From Operations | 3,288.61 | 3,219.32 | 3,085.55 | 3,224.29 | 3,207.59 | |
| EXPENDITURE | ||||||
| Consumption of Raw Materials | 1,086.96 | 791.44 | 794.42 | 1,053.72 | 984.84 | |
| Purchase of Traded Goods | 189.49 | 138.51 | 162.79 | 152.46 | 135.71 | |
| Increase/Decrease in Stocks | 10.40 | 314.40 | 157.41 | 4.28 | 47.56 | |
| Power & Fuel | -- | -- | -- | -- | -- | |
| Employees Cost | 565.81 | 456.31 | 513.67 | 487.73 | 534.19 | |
| Depreciation | 65.49 | 52.05 | 54.23 | 59.37 | 58.83 | |
| Excise Duty | -- | -- | -- | -- | -- | |
| Admin. And Selling Expenses | -- | -- | -- | -- | -- | |
| R & D Expenses | -- | -- | -- | -- | -- | |
| Provisions And Contingencies | -- | -- | -- | -- | -- | |
| Exp. Capitalised | -- | -- | -- | -- | -- | |
| Other Expenses | 746.78 | 900.55 | 747.90 | 928.99 | 754.88 | |
| P/L Before Other | 623.69 | 566.05 | 655.15 | 537.74 | 691.56 | |
| Other Income | 261.01 | 83.75 | 391.87 | 81.53 | 98.89 | |
| P/L Before Int. | 884.69 | 649.80 | 1,047.01 | 619.27 | 790.46 | |
| Interest | 133.24 | 107.79 | 116.02 | 97.72 | 93.18 | |
| P/L Before Exceptional Items & Tax | 751.45 | 542.01 | 930.99 | 521.55 | 697.28 | |
| Exceptional Items | -- | -- | 345.19 | -- | -- | |
| P/L Before Tax | 751.45 | 542.01 | 1,276.17 | 521.55 | 697.28 | |
| Tax | 91.62 | 91.30 | 238.58 | 105.92 | 98.56 | |
| P/L After Tax from Ordinary Activities | 659.84 | 450.71 | 1,037.59 | 415.63 | 598.72 | |
| Prior Year Adjustments | -- | -- | -- | -- | -- | |
| Extra Ordinary Items | -- | 26.45 | 107.36 | -- | -- | |
| Net Profit/(Loss) For the Period | 659.84 | 477.16 | 1,144.95 | 415.63 | 598.72 | |
| Equity Share Capital | 28.22 | 28.22 | 28.22 | 28.22 | 28.22 | |
| Reserves Excluding Revaluation Reserves | -- | -- | -- | -- | -- | |
| Equity Dividend Rate (%) | -- | -- | -- | -- | -- | |
| EPS Before Extra Ordinary | ||||||
| Basic EPS | 23.38 | -- | 40.58 | -- | 21.22 | |
| Diluted EPS | 23.38 | -- | 40.58 | -- | 21.21 | |
| EPS After Extra Ordinary | ||||||
| Basic EPS. | 23.38 | -- | 40.58 | -- | 21.22 | |
| Diluted EPS. | 23.38 | -- | 40.58 | -- | 21.21 | |
| Public Share Holding | ||||||
| No Of Shares (Crores) | -- | -- | -- | -- | -- | |
| Share Holding (%) | -- | -- | -- | -- | -- | |
| Promoters and Promoter Group Shareholding | ||||||
| a) Pledged/Encumbered | ||||||
| - Number of shares (Crores) | -- | -- | -- | -- | -- | |
| - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | -- | -- | |
| - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | -- | -- | |
| b) Non-encumbered | ||||||
| - Number of shares (Crores). | -- | -- | -- | -- | -- | |
| - Per. of shares (as a % of the total sh. of prom. and promoter group). | -- | -- | -- | -- | -- | |
| - Per. of shares (as a % of the total Share Cap. of the company). | -- | -- | -- | -- | -- |
22.01.2020
Glenmark Pharma sells gynaecology business, share price gains
07.01.2020
Granules India, Glenmark Pharma rally 3% on drug approvals from USFDA
16.12.2019
Glenmark Pharma receives GMP certificate from European regulator; share price gains 3%
18.11.2019
Glenmark Pharma share price ends 22% higher after CLSA upgrades stock to buy
31.05.2019
Glenmark Pharma wilts 3% on muted Q4 show, CLSA downgrades to sell
09.02.2018
Glenmark Pharma tanks 9% after disappointing Q3 earnings, US pricing pressure to continue
28.07.2017
31.07.2015
